The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2015 | Design and results of pacritinib for myelofibrosis trial (PERSIST-1)
Jean-Jacques Kiladjian
• 2 Jun 2015
Dr Jean-Jacques Kiladjian, at the 2015 American Society of Clinical Oncology (ASCO), describes the design and recent results of the PERSIST- 1 trial of pacritinib for patients with myelofibrosis, with specific focus on the impact on thrombocytopenia, low-platelet count, and transfusion independence.
